Comparing Innovation Spending: Amgen Inc. and Amicus Therapeutics, Inc.

A Decade of Innovation: Amgen Inc. vs. Amicus Therapeutics, Inc.

In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Amgen Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.

Amgen Inc.: A Giant's Steady March

From 2014 to 2023, Amgen Inc. consistently allocated substantial resources to R&D, with an average annual expenditure of approximately $4.2 billion. This unwavering commitment underscores Amgen's strategy to maintain its leadership in the biotech sector.

Amicus Therapeutics, Inc.: A Rising Star

In contrast, Amicus Therapeutics, Inc. has shown a remarkable growth trajectory in R&D spending, increasing from $47 million in 2014 to a peak of $308 million in 2020. This represents a staggering 550% increase, highlighting Amicus's aggressive push towards innovation.

Both companies exemplify different yet successful strategies in the pursuit of groundbreaking therapies.